1-anilino-8-naphthalenesulfonate has been researched along with Cardiovascular Diseases in 67 studies
1-anilino-8-naphthalenesulfonate: RN given refers to parent cpd
8-anilinonaphthalene-1-sulfonic acid : A naphthalenesulfonic acid that is naphthalene-1-sulfonic acid substituted by a phenylamino group at position 8.
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate serum amylase and lipase levels and the rate of acute pancreatitis in patients with type 2 diabetes and high cardiovascular risk randomized to liraglutide or placebo and observed for 3." | 9.24 | Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial. ( Buse, JB; Ghorbani, MLM; Nauck, MA; Steinberg, WM; Ørsted, DD, 2017) |
| "This study demonstrates the effectiveness of an intervention combining orlistat and lifestyle modification with Mexican-American women, a population with substantial risk for obesity." | 9.10 | Weight loss in obese Mexican Americans treated for 1-year with orlistat and lifestyle modification. ( Balasubramanyam, A; Foreyt, JP; Haddock, CK; Poston, WS; Reeves, RS; Satterwhite, O; Stormer, S; Taylor, JE, 2003) |
| "Orlistat was well tolerated." | 6.71 | The ORLIstat and CArdiovascular risk profile in patients with metabolic syndrome and type 2 DIAbetes (ORLICARDIA) Study. ( Athyros, VG; Bousboulas, SH; Didangelos, TP; Dimitriou, KC; Karamanos, BG; Karamitsos, DT; Pappas, SI; Sambanis, CL; Spanou, EA; Thanopoulou, AK, 2004) |
| "To evaluate serum amylase and lipase levels and the rate of acute pancreatitis in patients with type 2 diabetes and high cardiovascular risk randomized to liraglutide or placebo and observed for 3." | 5.24 | Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial. ( Buse, JB; Ghorbani, MLM; Nauck, MA; Steinberg, WM; Ørsted, DD, 2017) |
| "This study demonstrates the effectiveness of an intervention combining orlistat and lifestyle modification with Mexican-American women, a population with substantial risk for obesity." | 5.10 | Weight loss in obese Mexican Americans treated for 1-year with orlistat and lifestyle modification. ( Balasubramanyam, A; Foreyt, JP; Haddock, CK; Poston, WS; Reeves, RS; Satterwhite, O; Stormer, S; Taylor, JE, 2003) |
| "Two-year treatment with orlistat plus diet significantly promotes weight loss, lessens weight regain, and improves some obesity-related disease risk factors." | 5.09 | Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. ( Chung, J; Davidson, MH; DiGirolamo, M; Foreyt, JP; Halsted, CH; Hauptman, J; Heber, D; Heimburger, DC; Heymsfield, SB; Lucas, CP; Robbins, DC, 1999) |
| "The use of orlistat during periods of attempted weight maintenance minimizes weight readjustment and facilitates long-term improvement in obesity-related disease risk factors." | 5.09 | Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. ( Anderson, JW; Aronne, LJ; Fujioka, K; Hauptman, J; Hill, JO; O'Neil, PM; Smith, DK; Zavoral, JH, 1999) |
| " Sixty-eight women in pre-menopause (PMW) and 216 in post-menopause (POMW) were recruited; eighty-three had undergone HRT for at least 12 months, where 48 received conjugated estrogens alone (EHRT) and 35 received conjugated estrogen and medroxyprogesterone acetate (CHRT)." | 3.77 | Post-menopausal hormone therapy reduces autoantibodies to oxidized apolipoprotein B100. ( Castanho, VS; de Faria, EC; Gidlund, M; Nakamura, R, 2011) |
| "MAFLD is closely intertwined with type 2 diabetes, obesity, dyslipidaemia, all linked to a rise in the risk of cardiovascular disease (CVDs)." | 2.72 | Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches. ( Corsini, A; Dongiovanni, P; Paolini, E; Ruscica, M; Sirtori, CR, 2021) |
| "Orlistat was well tolerated." | 2.71 | The ORLIstat and CArdiovascular risk profile in patients with metabolic syndrome and type 2 DIAbetes (ORLICARDIA) Study. ( Athyros, VG; Bousboulas, SH; Didangelos, TP; Dimitriou, KC; Karamanos, BG; Karamitsos, DT; Pappas, SI; Sambanis, CL; Spanou, EA; Thanopoulou, AK, 2004) |
| "Non-alcoholic fatty liver disease (NAFLD) is highly prevalent among individuals with type 2 diabetes." | 2.66 | Non-alcoholic fatty liver disease and cardiovascular disease: assessing the evidence for causality. ( Brouwers, MCGJ; Isaacs, A; Simons, N; Stehouwer, CDA, 2020) |
| "Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in Western countries and expose patients to increased risk of hepatic and cardiovascular (CV) morbidity and mortality." | 2.66 | Nutrients, Genetic Factors, and Their Interaction in Non-Alcoholic Fatty Liver Disease and Cardiovascular Disease. ( Fargion, S; Fracanzani, AL; Iuculano, F; Lombardi, R; Pallini, G, 2020) |
| "In some patients with NAFLD, isolated steatosis can progress to advanced stages with non-alcoholic steatohepatitis (NASH) and fibrosis, increasing the risk of cirrhosis and hepatocellular carcinoma." | 2.61 | Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. ( Cusi, K; Häring, HU; Stefan, N, 2019) |
| "Posttransplant metabolic syndrome is a common occurrence that increases the risk of steatosis in the graft liver." | 2.58 | Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis in Liver Transplantation. ( Carter, D; Chang, C; Dieterich, DT, 2018) |
| "The characteristic dyslipidemia of insulin resistance consists of elevated triglyceride and triglyceride-rich lipoprotein levels, low levels of high-density lipoprotein cholesterol, and increased concentrations of small, dense low-density lipoprotein cholesterol." | 2.41 | Pathophysiology and treatment of the dyslipidemia of insulin resistance. ( Capuzzi , DM; Cohn, G; Valdes, G, 2001) |
| "Orlistat is a new inhibitor of pancreatic lipase enzyme." | 2.40 | New aspects in the management of obesity: operation and the impact of lipase inhibitors. ( Uusitupa, M, 1999) |
| "To investigate the effects of the NAFLD risk alleles on the all-cause and cause-specific mortality in 5581 Chinese adults." | 1.72 | NAFLD-related gene polymorphisms and all-cause and cause-specific mortality in an Asian population: the Shanghai Changfeng Study. ( Aleteng, Q; Chen, L; Gao, X; Ge, J; He, W; Hu, Y; Huang, Q; Li, Q; Li, X; Lin, H; Ma, H; Ma, S; Pan, B; Tang, H; Wang, S; Wu, L; Wu, Q; Xia, M; Xu, W; Zeng, H; Zheng, Y, 2022) |
| "Fatty liver is a potentially preventable cause of serious liver diseases." | 1.43 | Childhood predictors of adult fatty liver. The Cardiovascular Risk in Young Finns Study. ( Ahola-Olli, A; Hutri-Kähönen, N; Jokinen, E; Jula, A; Juonala, M; Kähönen, M; Laitinen, T; Lehtimäki, T; Loo, BM; Mikkilä, V; Oikonen, M; Parkkola, R; Pitkänen, N; Raitakari, OT; Suomela, E; Taittonen, L; Telama, R; Tossavainen, P; Viikari, JSA; Virtanen, J, 2016) |
| "Metabolic syndrome was defined according to ATPIII modified criteria." | 1.40 | Non-alcoholic fatty liver disease, metabolic syndrome and patatin-like phospholipase domain-containing protein3 gene variants. ( Angelico, F; Arca, M; Baratta, F; Brancorsini, M; D'Erasmo, L; Del Ben, M; Di Costanzo, A; Loffredo, L; Pastori, D; Pignatelli, P; Polimeni, L; Violi, F, 2014) |
| "The higher hepatic lipase activity in NAFLD patients contributes to a more atherogenic profile linked to increased cardiovascular risk, beyond the insulin resistance and the reduction in adiponectin." | 1.38 | Hepatic lipase activity is increased in non-alcoholic fatty liver disease beyond insulin resistance. ( Berg, G; Cacciagiú, L; Fassio, E; Gonzalez Ballerga, E; Lopez, G; Lucero, D; Miksztowicz, V; Schreier, L; Sordá, J; Zago, V, 2012) |
| "For the case-control studies, 2110 ischemic heart disease patients vs." | 1.35 | Hepatic lipase, genetically elevated high-density lipoprotein, and risk of ischemic cardiovascular disease. ( Andersen, RV; Jensen, GB; Johannsen, TH; Kamstrup, PR; Nordestgaard, BG; Sillesen, H; Tybjaerg-Hansen, A, 2009) |
| " We found a consistent and highly significant gene-nutrient interaction showing a strong dose-response effect." | 1.31 | Dietary fat intake determines the effect of a common polymorphism in the hepatic lipase gene promoter on high-density lipoprotein metabolism: evidence of a strong dose effect in this gene-nutrient interaction in the Framingham Study. ( Coltell, O; Corella, D; Couture, P; Cupples, LA; Demissie, S; Ordovas, JM; Schaefer, EJ; Tucker, KL; Wilson, PW, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (11.94) | 18.7374 |
| 1990's | 6 (8.96) | 18.2507 |
| 2000's | 23 (34.33) | 29.6817 |
| 2010's | 20 (29.85) | 24.3611 |
| 2020's | 10 (14.93) | 2.80 |
| Authors | Studies |
|---|---|
| Xia, M | 1 |
| Ma, S | 1 |
| Huang, Q | 1 |
| Zeng, H | 1 |
| Ge, J | 1 |
| Xu, W | 1 |
| Wu, Q | 1 |
| Wu, L | 1 |
| Li, X | 1 |
| Ma, H | 1 |
| Chen, L | 1 |
| Li, Q | 1 |
| Aleteng, Q | 1 |
| Hu, Y | 1 |
| He, W | 1 |
| Pan, B | 1 |
| Lin, H | 1 |
| Zheng, Y | 1 |
| Wang, S | 1 |
| Tang, H | 1 |
| Gao, X | 1 |
| Fraga, LN | 1 |
| Milenkovic, D | 1 |
| Coutinho, CP | 1 |
| Rozenbaum, AC | 1 |
| Lajolo, FM | 1 |
| Hassimotto, NMA | 1 |
| Silbernagel, G | 1 |
| Chen, YQ | 1 |
| Rief, M | 1 |
| Kleber, ME | 2 |
| Hoffmann, MM | 1 |
| Stojakovic, T | 1 |
| Stang, A | 1 |
| Sarzynski, MA | 1 |
| Bouchard, C | 2 |
| März, W | 2 |
| Qian, YW | 1 |
| Scharnagl, H | 1 |
| Konrad, RJ | 1 |
| Meng, W | 1 |
| Adam, LP | 1 |
| Behnia, K | 1 |
| Zhao, L | 1 |
| Yang, R | 1 |
| Kopcho, LM | 1 |
| Locke, GA | 1 |
| Taylor, DS | 1 |
| Yin, X | 1 |
| Wexler, RR | 1 |
| Finlay, H | 1 |
| Brouwers, MCGJ | 1 |
| Simons, N | 1 |
| Stehouwer, CDA | 1 |
| Isaacs, A | 1 |
| Wijarnpreecha, K | 1 |
| Scribani, M | 1 |
| Raymond, P | 1 |
| Harnois, DM | 1 |
| Keaveny, AP | 1 |
| Ahmed, A | 1 |
| Kim, D | 1 |
| Hara, Y | 3 |
| Zhang, B | 3 |
| Suzuki, A | 3 |
| Yamaguchi, S | 3 |
| Adachi, J | 1 |
| Tomonaga, T | 1 |
| Yasunaga, S | 1 |
| Saku, K | 1 |
| Aoyama, T | 2 |
| Hirano, KI | 3 |
| Lombardi, R | 1 |
| Iuculano, F | 1 |
| Pallini, G | 1 |
| Fargion, S | 1 |
| Fracanzani, AL | 1 |
| Dongiovanni, P | 1 |
| Paolini, E | 1 |
| Corsini, A | 1 |
| Sirtori, CR | 1 |
| Ruscica, M | 1 |
| Nagayama, D | 1 |
| Saiki, A | 1 |
| Watanabe, Y | 1 |
| Yamaguchi, T | 1 |
| Ohira, M | 1 |
| Sato, N | 1 |
| Kanayama, M | 1 |
| Moroi, M | 1 |
| Miyashita, Y | 1 |
| Shirai, K | 1 |
| Tatsuno, I | 1 |
| Salazar-Tortosa, DF | 1 |
| Pascual-Gamarra, JM | 1 |
| Labayen, I | 1 |
| Rupérez, AI | 1 |
| Censi, L | 1 |
| Béghin, L | 1 |
| Michels, N | 1 |
| González-Gross, M | 1 |
| Manios, Y | 1 |
| Lambrinou, CP | 1 |
| Moreno, LA | 1 |
| Meirhaeghe, A | 1 |
| Castillo, MJ | 1 |
| Ruiz, JR | 1 |
| Steinberg, WM | 1 |
| Buse, JB | 1 |
| Ghorbani, MLM | 1 |
| Ørsted, DD | 1 |
| Nauck, MA | 1 |
| Carter, D | 1 |
| Dieterich, DT | 1 |
| Chang, C | 1 |
| Li, M | 2 |
| Miyauchi, H | 2 |
| Ikeda, Y | 4 |
| Higashi, M | 2 |
| Takagi, A | 2 |
| Nagasaka, H | 2 |
| Kobayashi, K | 3 |
| Magata, Y | 1 |
| Stefan, N | 2 |
| Häring, HU | 2 |
| Cusi, K | 1 |
| Rhainds, D | 1 |
| Tardif, JC | 1 |
| Hashimoto, C | 1 |
| Kozawa, J | 1 |
| Sugimura, K | 1 |
| Futsukaichi, Y | 1 |
| Zaima, N | 1 |
| Shrestha, R | 1 |
| Nakamura, H | 1 |
| Kawaguchi, K | 1 |
| Sai, E | 1 |
| Hui, SP | 1 |
| Nakano, Y | 1 |
| Sawamura, A | 1 |
| Inaba, T | 1 |
| Sakata, Y | 1 |
| Yasui, Y | 1 |
| Nagasawa, Y | 1 |
| Kinugawa, S | 1 |
| Shimada, K | 1 |
| Yamada, S | 1 |
| Hao, H | 1 |
| Nakatani, D | 1 |
| Ide, T | 1 |
| Amano, T | 1 |
| Naito, H | 1 |
| Pongprasobchai, S | 1 |
| Elshourbagy, NA | 1 |
| Meyers, HV | 1 |
| Abdel-Meguid, SS | 1 |
| Del Ben, M | 1 |
| Polimeni, L | 1 |
| Brancorsini, M | 1 |
| Di Costanzo, A | 1 |
| D'Erasmo, L | 1 |
| Baratta, F | 1 |
| Loffredo, L | 1 |
| Pastori, D | 1 |
| Pignatelli, P | 1 |
| Violi, F | 1 |
| Arca, M | 1 |
| Angelico, F | 1 |
| Posadas-Sánchez, R | 1 |
| Ocampo-Arcos, WA | 1 |
| López-Uribe, ÁR | 1 |
| Posadas-Romero, C | 1 |
| Villarreal-Molina, T | 1 |
| León, EÁ | 1 |
| Pérez-Hernández, N | 1 |
| Rodríguez-Pérez, JM | 1 |
| Cardoso-Saldaña, G | 1 |
| Medina-Urrutia, A | 1 |
| Vargas-Alarcón, G | 1 |
| Suomela, E | 1 |
| Oikonen, M | 1 |
| Pitkänen, N | 1 |
| Ahola-Olli, A | 1 |
| Virtanen, J | 1 |
| Parkkola, R | 1 |
| Jokinen, E | 1 |
| Laitinen, T | 1 |
| Hutri-Kähönen, N | 1 |
| Kähönen, M | 1 |
| Lehtimäki, T | 1 |
| Taittonen, L | 1 |
| Tossavainen, P | 1 |
| Jula, A | 1 |
| Loo, BM | 1 |
| Mikkilä, V | 1 |
| Telama, R | 1 |
| Viikari, JSA | 1 |
| Juonala, M | 1 |
| Raitakari, OT | 1 |
| Xu, L | 1 |
| Jiang, CQ | 1 |
| Lam, TH | 1 |
| Zhang, WS | 1 |
| Zhu, F | 1 |
| Jin, YL | 1 |
| Thomas, GN | 1 |
| Cheng, KK | 1 |
| Schooling, CM | 1 |
| Goodman, KB | 1 |
| Bury, MJ | 1 |
| Cheung, M | 1 |
| Cichy-Knight, MA | 1 |
| Dowdell, SE | 1 |
| Dunn, AK | 1 |
| Lee, D | 1 |
| Lieby, JA | 1 |
| Moore, ML | 1 |
| Scherzer, DA | 1 |
| Sha, D | 1 |
| Suarez, DP | 1 |
| Murphy, DJ | 1 |
| Harpel, MR | 1 |
| Manas, ES | 1 |
| McNulty, DE | 1 |
| Annan, RS | 1 |
| Matico, RE | 1 |
| Schwartz, BK | 1 |
| Trill, JJ | 1 |
| Sweitzer, TD | 1 |
| Wang, DY | 1 |
| Keller, PM | 1 |
| Krawiec, JA | 1 |
| Jaye, MC | 1 |
| Johannsen, TH | 1 |
| Kamstrup, PR | 1 |
| Andersen, RV | 1 |
| Jensen, GB | 1 |
| Sillesen, H | 1 |
| Tybjaerg-Hansen, A | 1 |
| Nordestgaard, BG | 1 |
| Fazio, S | 1 |
| Linton, MF | 1 |
| Mitchell, GA | 1 |
| Muntoni, S | 2 |
| Atzori, L | 1 |
| Mereu, R | 1 |
| Manca, A | 1 |
| Satta, G | 1 |
| Gentilini, A | 1 |
| Bianco, P | 1 |
| Baule, A | 1 |
| Baule, GM | 1 |
| Rosenson, RS | 1 |
| Johansen, CT | 1 |
| Gallinger, ZR | 1 |
| Wang, J | 1 |
| Ban, MR | 1 |
| Young, TK | 1 |
| Bjerregaard, P | 1 |
| Hegele, RA | 1 |
| Grammer, TB | 1 |
| Castanho, VS | 1 |
| Gidlund, M | 1 |
| Nakamura, R | 1 |
| de Faria, EC | 2 |
| Miksztowicz, V | 1 |
| Lucero, D | 1 |
| Zago, V | 1 |
| Cacciagiú, L | 1 |
| Lopez, G | 1 |
| Gonzalez Ballerga, E | 1 |
| Sordá, J | 1 |
| Fassio, E | 1 |
| Schreier, L | 1 |
| Berg, G | 1 |
| Ampuero, J | 1 |
| Romero-Gómez, M | 1 |
| Han, Z | 1 |
| Heath, SC | 1 |
| Shmulewitz, D | 1 |
| Li, W | 1 |
| Auerbach, SB | 1 |
| Blundell, ML | 1 |
| Lehner, T | 1 |
| Ott, J | 1 |
| Stoffel, M | 1 |
| Friedman, JM | 1 |
| Breslow, JL | 1 |
| Ordovas, JM | 3 |
| Corella, D | 2 |
| Demissie, S | 1 |
| Cupples, LA | 1 |
| Couture, P | 1 |
| Coltell, O | 1 |
| Wilson, PW | 1 |
| Schaefer, EJ | 1 |
| Tucker, KL | 1 |
| Zambon, A | 1 |
| Deeb, SS | 1 |
| Pauletto, P | 1 |
| Crepaldi, G | 1 |
| Brunzell, JD | 1 |
| Alarcon, SB | 1 |
| Oliveira, HC | 1 |
| Harada, LM | 1 |
| Nunes, VS | 1 |
| Kaplan, D | 1 |
| Quintão, EC | 1 |
| Rader, DJ | 1 |
| GOTTSEGEN, G | 1 |
| TOROK, E | 1 |
| Poston, WS | 1 |
| Reeves, RS | 1 |
| Haddock, CK | 1 |
| Stormer, S | 1 |
| Balasubramanyam, A | 1 |
| Satterwhite, O | 1 |
| Taylor, JE | 1 |
| Foreyt, JP | 2 |
| Didangelos, TP | 1 |
| Thanopoulou, AK | 1 |
| Bousboulas, SH | 1 |
| Sambanis, CL | 1 |
| Athyros, VG | 1 |
| Spanou, EA | 1 |
| Dimitriou, KC | 1 |
| Pappas, SI | 1 |
| Karamanos, BG | 1 |
| Karamitsos, DT | 1 |
| Hutter, CM | 1 |
| Austin, MA | 2 |
| Farin, FM | 1 |
| Viernes, HM | 1 |
| Edwards, KL | 2 |
| Leonetti, DL | 1 |
| McNeely, MJ | 1 |
| Fujimoto, WY | 1 |
| Nelson, RH | 1 |
| Miles, JM | 1 |
| Miljkovic-Gacic, I | 1 |
| Bunker, CH | 1 |
| Ferrell, RE | 1 |
| Kammerer, CM | 1 |
| Evans, RW | 1 |
| Patrick, AL | 1 |
| Kuller, LH | 1 |
| Paradis, ME | 1 |
| Lamarche, B | 1 |
| Annuzzi, G | 1 |
| Santo, AS | 1 |
| Cunningham, AM | 1 |
| Alhassan, S | 1 |
| Browne, RW | 1 |
| Burton, H | 1 |
| Leddy, JJ | 1 |
| Grandjean, PW | 1 |
| Horvath, SM | 1 |
| Horvath, PJ | 1 |
| Lacour, B | 1 |
| Roullet, JB | 1 |
| Drueke, T | 1 |
| Pérusse, L | 1 |
| Rice, T | 1 |
| Després, JP | 1 |
| Bergeron, J | 1 |
| Province, MA | 1 |
| Gagnon, J | 1 |
| Leon, AS | 1 |
| Rao, DC | 1 |
| Skinner, JS | 1 |
| Wilmore, JH | 1 |
| Zavoral, JH | 2 |
| Davidson, MH | 1 |
| Hauptman, J | 3 |
| DiGirolamo, M | 1 |
| Halsted, CH | 1 |
| Heber, D | 1 |
| Heimburger, DC | 1 |
| Lucas, CP | 1 |
| Robbins, DC | 1 |
| Chung, J | 1 |
| Heymsfield, SB | 1 |
| Uusitupa, M | 1 |
| Hill, JO | 1 |
| Anderson, JW | 1 |
| Fujioka, K | 1 |
| O'Neil, PM | 1 |
| Smith, DK | 1 |
| Aronne, LJ | 1 |
| Lucas, C | 1 |
| Boldrin, MN | 1 |
| Collins, H | 1 |
| Segal, KR | 1 |
| Friedlander, Y | 1 |
| Talmud, PJ | 1 |
| Humphries, SE | 1 |
| Cohn, G | 1 |
| Valdes, G | 1 |
| Capuzzi , DM | 1 |
| Shen, H | 1 |
| Alexander, JP | 1 |
| Barron, DW | 1 |
| Blomhoff, JP | 1 |
| Hayakawa, T | 1 |
| Kondo, T | 1 |
| Shibata, T | 1 |
| Kitagawa, M | 1 |
| Ono, H | 1 |
| Sakai, Y | 1 |
| Kiriyama, S | 1 |
| Haffner, SM | 1 |
| Fong, D | 1 |
| Hazuda, HP | 1 |
| Pugh, JA | 1 |
| Patterson, JK | 1 |
| Crona, N | 1 |
| Enk, L | 1 |
| Mattsson, LA | 1 |
| Samsioe, G | 1 |
| Silfverstolpe, G | 1 |
| Williams, PT | 1 |
| Krauss, RM | 1 |
| Wood, PD | 1 |
| Lindgren, FT | 1 |
| Giotas, C | 1 |
| Vranizan, KM | 1 |
| Förster, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Long-term, Multi-centre, International, Randomised Double-blind, Placebo-controlled Trial to Determine Liraglutide Effects on Cardiovascular Events[NCT01179048] | Phase 3 | 9,341 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| The Role of Microbiome Reprogramming on Liver Fat Accumulation[NCT03914495] | 57 participants (Actual) | Interventional | 2019-05-21 | Terminated (stopped due to PI carefully considered multiple factors and decided to close study to any further enrollment.) | |||
| Comparative Clinical Study to Evaluate the Possible Beneficial Effect of Empagliflozin Versus Pioglitazone on Non-diabetic Patients With Non-Alcoholic Steatohepatitis[NCT05605158] | Phase 3 | 56 participants (Anticipated) | Interventional | 2022-11-30 | Not yet recruiting | ||
| A Randomised Controlled International Multicentre Study Evaluating Changes in Metabolic Syndrome in Smokers With Type 2 Diabetes Mellitus After Switching From Tobacco Cigarettes to Combustion-Free Nicotine Delivery Systems: DIASMOKE Study[NCT04231838] | 576 participants (Anticipated) | Interventional | 2021-09-27 | Recruiting | |||
| Health, Risk Factors, Exercise Training, and Genetics[NCT00005137] | 0 participants | Interventional | 1992-07-31 | Completed | |||
| Diabetes and Cardiovascular Risk In Mexico City (San Antonio Heart Study)[NCT00005146] | 0 participants | Observational | 1979-05-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Time from randomisation to first occurrence of an expanded composite cardiovascular outcome defined as either cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularisation, hospitalisation for unstable angina or for heart failure. The percentage of subjects experiencing first occurrence of an expanded composite cardiovascular outcome defined as either cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularisation, hospitalisation for unstable angina or for heart failure is presented. (NCT01179048)
Timeframe: from randomisation (visit 3; month 0) to last contact (visit 16; up to month 60+30 days)
| Intervention | percentage of subjects (Number) |
|---|---|
| Liraglutide | 20.3 |
| Placebo | 22.7 |
Time from randomisation to all cause death. The percentage of subjects with a death by any cause (all-cause death) is presented. (NCT01179048)
Timeframe: from randomisation (visit 3; month 0) to last contact (visit 16; up to month 60+30 days)
| Intervention | percentage of subjects (Number) |
|---|---|
| Liraglutide | 8.2 |
| Placebo | 9.6 |
"Time from randomisation to first occurrence of a composite microvascular outcome, defined as any one of the following:~new onset of persistent macroalbuminuria~persistent doubling of serum creatinine~need for continuous renal replacement therapy~death due to renal disease~need for retinal photocoagulation or treatment with intravitreal agents~vitreous haemorrhage~diabetes-related blindness~The percentage of subjects experiencing a first occurrence of a composite microvascular outcome is presented." (NCT01179048)
Timeframe: from randomisation (visit 3; month 0) to last contact (visit 16; up to month 60+30 days)
| Intervention | Percentage of subjects (Number) |
|---|---|
| Liraglutide | 7.6 |
| Placebo | 8.9 |
Time from randomisation to first occurrence of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke (a composite cardiovascular outcome). The percentage of subjects experiencing a first event of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke (a composite cardiovascular outcome) is presented. (NCT01179048)
Timeframe: from randomisation (visit 3; month 0) to last contact (visit 16; up to month 60+30 days)
| Intervention | percentage of subjects (Number) |
|---|---|
| Liraglutide | 13.0 |
| Placebo | 14.9 |
Time from randomisation to each individual component of the composite microvascular outcome and to the retinopathy and nephropathy composite outcomes separately. The percentage of subjects experiencing each individual component of the composite microvascular outcome are presented. (NCT01179048)
Timeframe: from randomisation (visit 3; month 0) to last contact (visit 16; up to month 60+30 days)
| Intervention | Percentage of subjects (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Nephropathy composite | New onset of persistent macroalbuminuria | Persistent doubling of serum creatinine | Need for continuous renal-replacement therapy | Death due to renal disease | Retinopathy composite | Treatment with photocoagulation/intravitreal agent | Development of diabetes-related blindness | Vitreous haemorrhage | |
| Liraglutide | 5.7 | 3.4 | 1.9 | 1.2 | 0.2 | 2.3 | 2.1 | 0.0 | 0.7 |
| Placebo | 7.2 | 4.6 | 2.1 | 1.4 | 0.1 | 2.0 | 1.8 | 0.02 | 0.5 |
Time from randomisation to each individual component of the expanded composite cardiovascular outcome. The percentage of subjects experiencing each of the individual component of the expanded composite cardiovascular outcome (defined as either cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularisation, hospitalisation for unstable angina or heart failure) is presented. (NCT01179048)
Timeframe: from randomisation (visit 3; month 0) to last contact (visit 16; up to month 60+30 days)
| Intervention | percentage of subjects (Number) | |||||
|---|---|---|---|---|---|---|
| Cardiovascular death | Non-fatal stroke | Non-fatal myocardial infarction | Unstable angina pectoris (hospitalisation) | Coronary revascularisation | Heart failure (hospitalisation) | |
| Liraglutide | 4.7 | 3.4 | 6.0 | 2.6 | 8.7 | 4.7 |
| Placebo | 6.0 | 3.8 | 6.8 | 2.7 | 9.4 | 5.3 |
23 reviews available for 1-anilino-8-naphthalenesulfonate and Cardiovascular Diseases
| Article | Year |
|---|---|
Non-alcoholic fatty liver disease and cardiovascular disease: assessing the evidence for causality.
Topics: Animals; Cardiovascular Diseases; Humans; Lipase; Membrane Proteins; Non-alcoholic Fatty Liver Disea | 2020 |
Nutrients, Genetic Factors, and Their Interaction in Non-Alcoholic Fatty Liver Disease and Cardiovascular Disease.
Topics: Apolipoproteins; Cardiovascular Diseases; Diet; Epigenesis, Genetic; Fatty Acids, Unsaturated; Fruct | 2020 |
Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches.
Topics: Acyltransferases; Cardiovascular Diseases; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dysli | 2021 |
Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis in Liver Transplantation.
Topics: Cardiovascular Diseases; Diabetes Complications; Humans; Kidney Diseases; Lipase; Liver Transplantat | 2018 |
Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies.
Topics: Antioxidants; Bariatric Surgery; Carcinoma, Hepatocellular; Cardiovascular Diseases; Diabetes Mellit | 2019 |
Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies.
Topics: Antioxidants; Bariatric Surgery; Carcinoma, Hepatocellular; Cardiovascular Diseases; Diabetes Mellit | 2019 |
Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies.
Topics: Antioxidants; Bariatric Surgery; Carcinoma, Hepatocellular; Cardiovascular Diseases; Diabetes Mellit | 2019 |
Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies.
Topics: Antioxidants; Bariatric Surgery; Carcinoma, Hepatocellular; Cardiovascular Diseases; Diabetes Mellit | 2019 |
From HDL-cholesterol to HDL-function: cholesterol efflux capacity determinants.
Topics: Antigens, Nuclear; Apolipoprotein A-I; Apolipoproteins E; Biological Assay; Biological Transport; Bi | 2019 |
Maldigestion from pancreatic exocrine insufficiency.
Topics: Administration, Oral; Atherosclerosis; Breath Tests; Cardiovascular Diseases; Diet, Fat-Restricted; | 2013 |
Cholesterol: the good, the bad, and the ugly - therapeutic targets for the treatment of dyslipidemia.
Topics: Animals; Apolipoprotein A-I; Apolipoproteins B; Atherosclerosis; Cardiovascular Diseases; Cholestero | 2014 |
Genetics, physiology and perinatal influences in childhood obesity: view from the Chair.
Topics: Adipocytes; Adipose Tissue; Adult; Age of Onset; Cardiovascular Diseases; Child; Fatty Acids; Female | 2009 |
[High-density lipoprotein (HDL) and cholesteryl ester transfer protein (CETP): role in lipid metabolism and clinical meaning].
Topics: Anticholesteremic Agents; Apolipoprotein A-I; Cardiovascular Diseases; Cholesterol Ester Transfer Pr | 2010 |
[Influence of non-alcoholic fatty liver disease on cardiovascular disease].
Topics: Apolipoprotein C-III; Atherosclerosis; Cardiovascular Diseases; Carotid Intima-Media Thickness; Chol | 2012 |
Hepatic lipase: a marker for cardiovascular disease risk and response to therapy.
Topics: Animals; Cardiovascular Diseases; Genetic Predisposition to Disease; Humans; Lipase; Liver; Polymorp | 2003 |
Regulation of reverse cholesterol transport and clinical implications.
Topics: Animals; Apolipoprotein A-I; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; | 2003 |
Genes, diet and plasma lipids: the evidence from observational studies.
Topics: Apolipoproteins; Cardiovascular Diseases; Diet; Gene Frequency; Genetic Predisposition to Disease; G | 2004 |
The use of orlistat in the treatment of obesity, dyslipidaemia and Type 2 diabetes.
Topics: Anti-Obesity Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diet, Fat-Restricted; Dysli | 2005 |
Endothelial lipase: its role in cardiovascular disease.
Topics: Animals; Apolipoproteins; Cardiovascular Diseases; Cholesterol, HDL; Humans; Lipase; Lipid Metabolis | 2006 |
[Lipid metabolism disorders in chronic kidney failure].
Topics: Apoproteins; Cardiovascular Diseases; Hormones; Humans; Kidney Failure, Chronic; Lipase; Lipids; Lip | 1983 |
New aspects in the management of obesity: operation and the impact of lipase inhibitors.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Humans; Lactones; Lipase; Mul | 1999 |
Pathophysiology and treatment of the dyslipidemia of insulin resistance.
Topics: Cardiovascular Diseases; Enzyme Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; | 2001 |
Pharmacogenetics of Lipid-lowering Therapies.
Topics: Apolipoproteins E; Aryldialkylphosphatase; ATP Binding Cassette Transporter 1; ATP-Binding Cassette | 2002 |
Lipoproteins, lipases, and the metabolic cardiovascular syndrome.
Topics: Blood Glucose; Cardiovascular Diseases; Coronary Disease; Down-Regulation; Eating; Fatty Acids, None | 1992 |
Progestogens and lipid metabolism.
Topics: Adipose Tissue; Animals; Cardiovascular Diseases; Chemical Phenomena; Chemistry; Drug Combinations; | 1986 |
[Prostaglandins and cardiovascular diseases].
Topics: Adolescent; Animals; Animals, Laboratory; Arteriosclerosis; Blood Coagulation Disorders; Cardiovascu | 1972 |
9 trials available for 1-anilino-8-naphthalenesulfonate and Cardiovascular Diseases
| Article | Year |
|---|---|
Prevention of Cardiovascular Events with Pitavastatin is Associated with Increased Serum Lipoprotein Lipase Mass Level: Subgroup Analysis of the TOHO-LIP.
Topics: Cardiovascular Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipase; Lipoprotein | 2022 |
Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial.
Topics: Acute Disease; Amylases; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Fe | 2017 |
Weight loss in obese Mexican Americans treated for 1-year with orlistat and lifestyle modification.
Topics: Adult; Aged; Anti-Obesity Agents; Behavior Therapy; Cardiovascular Diseases; Combined Modality Thera | 2003 |
The ORLIstat and CArdiovascular risk profile in patients with metabolic syndrome and type 2 DIAbetes (ORLICARDIA) Study.
Topics: Anti-Obesity Agents; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diet, Reduci | 2004 |
NMR analysis of lipoprotein particle size does not increase sensitivity to the effect of soy protein on CVD risk when compared with the traditional lipid profile.
Topics: Adolescent; Adult; Apolipoproteins; Blood Glucose; Cardiovascular Diseases; Cholesterol; Cholesterol | 2008 |
Treatment with orlistat reduces cardiovascular risk in obese patients.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Diet, Reducing; Double-Blind Me | 1998 |
Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial.
Topics: Adult; Analysis of Variance; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Double-Blind Me | 1999 |
Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study.
Topics: Adult; Anti-Obesity Agents; Behavior Therapy; Cardiovascular Diseases; Cholesterol, HDL; Dietary Fat | 1999 |
Orlistat in the long-term treatment of obesity in primary care settings.
Topics: Adult; Anti-Obesity Agents; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Double-Blind Met | 2000 |
35 other studies available for 1-anilino-8-naphthalenesulfonate and Cardiovascular Diseases
| Article | Year |
|---|---|
NAFLD-related gene polymorphisms and all-cause and cause-specific mortality in an Asian population: the Shanghai Changfeng Study.
Topics: Adult; Cardiovascular Diseases; Cause of Death; China; Genetic Predisposition to Disease; Genome-Wid | 2022 |
Interaction between APOE, APOA1, and LPL Gene Polymorphisms and Variability in Changes in Lipid and Blood Pressure following Orange Juice Intake: A Pilot Study.
Topics: Apolipoprotein A-I; Apolipoproteins E; Blood Pressure; Cardiovascular Diseases; Citrus sinensis; Fla | 2023 |
Inverse association between apolipoprotein C-II and cardiovascular mortality: role of lipoprotein lipase activity modulation.
Topics: Apolipoprotein C-II; Apolipoprotein C-III; Cardiovascular Diseases; Humans; Lipase; Lipoprotein Lipa | 2023 |
Benzothiazole-based compounds as potent endothelial lipase inhibitors.
Topics: Animals; Benzothiazoles; Cardiovascular Diseases; Drug Evaluation, Preclinical; Enzyme Inhibitors; G | 2019 |
PNPLA3 gene polymorphism and overall and cardiovascular mortality in the United States.
Topics: Adult; Alleles; Cardiovascular Diseases; Comorbidity; Female; Follow-Up Studies; Genetic Association | 2020 |
Effect of Tricaprin on Cardiac Proteome in a Mouse Model for Triglyceride Deposit Cardiomyovasculopathy.
Topics: Animals; Cardiovascular Diseases; Dietary Supplements; Disease Models, Animal; Female; Lipase; Lipol | 2020 |
Interplay of physical activity and genetic variants of the endothelial lipase on cardiovascular disease risk factors.
Topics: Adolescent; Cardiovascular Diseases; Exercise; Heart Disease Risk Factors; Humans; Lipase; Lipids; R | 2022 |
Tricaprin Rescues Myocardial Abnormality in a Mouse Model of Triglyceride Deposit Cardiomyovasculopathy.
Topics: Animals; Cardiovascular Diseases; Disease Models, Animal; Fatty Acids; Heart; Humans; Lipase; Mice, | 2018 |
Triglyceride deposit cardiomyovasculopathy: a rare cardiovascular disorder.
Topics: Adult; Aged; Atherosclerosis; Cardiovascular Diseases; Female; Humans; Lipase; Male; Middle Aged; Mu | 2019 |
Non-alcoholic fatty liver disease, metabolic syndrome and patatin-like phospholipase domain-containing protein3 gene variants.
Topics: Adult; Aged; Cardiovascular Diseases; Cohort Studies; Female; Genetic Predisposition to Disease; Hum | 2014 |
Hepatic lipase (LIPC) C-514T gene polymorphism is associated with cardiometabolic parameters and cardiovascular risk factors but not with fatty liver in Mexican population.
Topics: Adult; Aged; Apolipoprotein A-I; Biomarkers; Cardiovascular Diseases; Case-Control Studies; Choleste | 2015 |
Childhood predictors of adult fatty liver. The Cardiovascular Risk in Young Finns Study.
Topics: Adolescent; Cardiovascular Diseases; Child; Fatty Liver; Finland; Genetic Predisposition to Disease; | 2016 |
Mendelian randomization estimates of alanine aminotransferase with cardiovascular disease: Guangzhou Biobank Cohort study.
Topics: Alanine Transaminase; Biological Specimen Banks; Cardiovascular Diseases; Cohort Studies; Female; Ge | 2017 |
Discovery of potent, selective sulfonylfuran urea endothelial lipase inhibitors.
Topics: Animals; Cardiovascular Diseases; Drug Discovery; Drug Evaluation, Preclinical; Endothelium; Enzyme | 2009 |
Hepatic lipase, genetically elevated high-density lipoprotein, and risk of ischemic cardiovascular disease.
Topics: Adult; Amino Acid Substitution; Cardiovascular Diseases; Cerebral Hemorrhage; Cholesterol, HDL; Denm | 2009 |
Elevated high-density lipoprotein (HDL) levels due to hepatic lipase mutations do not reduce cardiovascular disease risk: another strike against the HDL dogma.
Topics: Cardiovascular Diseases; Carrier State; Cholesterol, HDL; Genetic Variation; Humans; Lipase; Lipopro | 2009 |
Risk factors for cardiovascular disease in Sardinia from 1978 to 2001: a comparative study with Italian mainland.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Apolipoproteins A; Blood Glucose; Cardiovascular D | 2009 |
Functional assessment of HDL: Moving beyond static measures for risk assessment.
Topics: Amides; Animals; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol; Cholest | 2010 |
Rare ATGL haplotypes are associated with increased plasma triglyceride concentrations in the Greenland Inuit.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Female; Genotype; Greenland; Ha | 2010 |
The metabolically benign and malignant fatty liver.
Topics: Animals; Cardiovascular Diseases; Child; Diabetes Mellitus, Type 1; Fatty Liver; Hepatitis; Humans; | 2011 |
Post-menopausal hormone therapy reduces autoantibodies to oxidized apolipoprotein B100.
Topics: Adult; Aged; Aged, 80 and over; Apolipoprotein B-100; Autoantibodies; Autoimmune Diseases; Cardiovas | 2011 |
Hepatic lipase activity is increased in non-alcoholic fatty liver disease beyond insulin resistance.
Topics: Atherosclerosis; Cardiovascular Diseases; Fatty Liver; Humans; Insulin Resistance; Lipase; Liver; No | 2012 |
Candidate genes involved in cardiovascular risk factors by a family-based association study on the island of Kosrae, Federated States of Micronesia.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Apolipoprotein A-I; Apolipoprotein A-II; Apolipoproteins E; | 2002 |
Dietary fat intake determines the effect of a common polymorphism in the hepatic lipase gene promoter on high-density lipoprotein metabolism: evidence of a strong dose effect in this gene-nutrient interaction in the Framingham Study.
Topics: Adult; Aged; Alleles; Cardiovascular Diseases; Cholesterol, HDL; Cohort Studies; Demography; Dietary | 2002 |
Moderate hyperalphalipoproteinaemia in a Brazilian population is related to lipoprotein lipase activity, apolipoprotein A-I concentration, age and body mass index.
Topics: Adult; Age Factors; Aged; Apolipoprotein A-I; Body Mass Index; Cardiovascular Diseases; Carrier Prot | 2004 |
[Studies on the treatment of circulatory diseases. II. Administration of vasolastine in coronary sclerosis].
Topics: Cardiovascular Diseases; Coronary Artery Disease; Coronary Disease; Enzyme Therapy; Enzymes; Humans; | 1960 |
Association of endothelial lipase gene (LIPG) haplotypes with high-density lipoprotein cholesterol subfractions and apolipoprotein AI plasma levels in Japanese Americans.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alleles; Apolipoprotein A-I; Asian; Cardiovascular Disea | 2006 |
Lipoprotein subclass and particle size differences in Afro-Caribbeans, African Americans, and white Americans: associations with hepatic lipase gene variation.
Topics: Adult; Age Factors; Aged; Alleles; Black or African American; Body Mass Index; Cardiovascular Diseas | 2006 |
Genetic and environmental modulation of postprandial lipemia: from a better knowledge of the mechanisms to a more effective treatment strategy.
Topics: Cardiovascular Diseases; Environment; Genetic Predisposition to Disease; Humans; Hyperlipidemias; Li | 2008 |
Familial resemblance of plasma lipids, lipoproteins and postheparin lipoprotein and hepatic lipases in the HERITAGE Family Study.
Topics: Adolescent; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus; Enzyme Induction; Exercise; | 1997 |
Sib-pair linkage analysis of longitudinal changes in lipoprotein risk factors and lipase genes in women twins.
Topics: Adult; Cardiovascular Diseases; Female; Genetic Linkage; Genetic Predisposition to Disease; Humans; | 2000 |
Biochemical disturbances associated with total hip replacement.
Topics: Arrhythmias, Cardiac; Arthroplasty; Bone Cements; Cardiovascular Diseases; Hip Joint; Humans; Hypote | 1979 |
Enzyme immunoassay for serum pancreatic lipase in the diagnosis of pancreatic diseases.
Topics: Adult; Amylases; Cardiovascular Diseases; Digestive System Diseases; Female; Humans; Immunoenzyme Te | 1989 |
Hyperinsulinemia, upper body adiposity, and cardiovascular risk factors in non-diabetics.
Topics: Adipose Tissue; Adult; Blood Pressure; Cardiovascular Diseases; Cholesterol, HDL; Female; Hispanic o | 1988 |
Lipoprotein subfractions of runners and sedentary men.
Topics: Adipose Tissue; Adult; Body Weight; Cardiovascular Diseases; Female; Humans; Lipase; Lipoprotein Lip | 1986 |